Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of
antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal products
were studied, including calcium channel blockers (amlodipine), angiotensin converting enzyme (ACE)
inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics
(bendroflumethiazide), and angiotensin II receptor blockers (various types and doses, alone or in
combination with thiazides, calcium channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil
(10 mg except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose was
applied) had no clinically significant interaction with any of these classes. In another clinical pharmacology
study tadalafil (20 mg) was studied in combination with up to 4 classes of antihypertensives. In subjects
taking multiple antihypertensives, the ambulatory-blood-pressure changes appeared to relate to the degree of
blood-pressure control. In this regard, study subjects whose blood pressure was well controlled, the reduction
was minimal and similar to that seen in healthy subjects. In study subjects whose blood pressure was not
controlled, the reduction was greater although this reduction was not associated with hypotensive symptoms
in the majority of subjects. In patients receiving concomitant antihypertensive medicinal products, tadalafil
20 mg may induce a blood pressure decrease, which (with the exception of alpha blockers -see above-) is, in
general, minor and not likely to be clinically relevant. Analysis of phase 3 clinical trial data showed no
difference in adverse events in patients taking tadalafil with or without antihypertensive medicinal products.
However, appropriate clinical advice should be given to patients regarding a possible decrease in blood
pressure when they are treated with antihypertensive medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of
antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal products
were studied, including calcium channel blockers (amlodipine), angiotensin converting enzyme (ACE)
inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics
(bendroflumethiazide), and angiotensin II receptor blockers (various types and doses, alone or in
combination with thiazides, calcium channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil
(10 mg except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose was
applied) had no clinically significant interaction with any of these classes. In another clinical pharmacology
study tadalafil (20 mg) was studied in combination with up to 4 classes of antihypertensives. In subjects
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
If brexpiprazole is administered concomitantly with medicinal products known to cause QT
prolongation (e.g. moxifloxacin) or electrolyte imbalance (e.g. diuretics such as furosemide,
bendroflumethiazide), caution should be used.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-03-12T14:38:00Z · SHA-256 d060cc667cc18af4e73efacd249c6f69ccb808c8be005b26cc608ba465837472 · Passage 6c1b40f0e66fdbcca786d1619b6e2681513cf8e2a825a1018aea4ae5ec915287 · Zeichen 2512–2740 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.